Summit Therapeutics PLC - Asset Resilience Ratio
Summit Therapeutics PLC (SMMT) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read SMMT liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2024)
This chart shows how Summit Therapeutics PLC's Asset Resilience Ratio has changed over time. See what is Summit Therapeutics PLC's book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Summit Therapeutics PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Summit Therapeutics PLC market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Summit Therapeutics PLC maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Summit Therapeutics PLC Industry Peers by Asset Resilience Ratio
Compare Summit Therapeutics PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Summit Therapeutics PLC (2004–2024)
The table below shows the annual Asset Resilience Ratio data for Summit Therapeutics PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 70.60% | $307.49 Million | $435.56 Million | +14.02pp |
| 2023-12-31 | 56.57% | $114.82 Million | $202.95 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $664.17 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $78.39 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $76.38 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $46.98 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $35.71 Million | -- |
| 2005-12-31 | 80.01% | $20.70 Million | $25.87 Million | +3.01pp |
| 2004-12-31 | 77.00% | $20.70 Million | $26.88 Million | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small… Read more